(Alliance News) - ProCook Group PLC on Wednesday said sales growth accelerated during its financial first half, leaving it on track to meet full-year market expectations. Read More
(Alliance News) - Cohort PLC on Wednesday reported a fall in its interim profit, despite a rise in revenue, due to increased administrative and finance costs. Read More
(Alliance News) - Polar Capital Technology Trust PLC on Wednesday played down fears of a bubble in technology valuations as it hailed a "remarkable" first half of its financial year. Read More
(Alliance News) - Berkeley Group Holdings PLC on Wednesday said housing undersupply in London, combined with an improvement in affordability due to lower interest rates, is improving its outlook. Read More
(Alliance News) - Beijing denounced on Wednesday British sanctions on two Chinese companies which London alleged were involved in cyber activities against Britain, saying the measure amounted to "political manipulation" of security issues. Read More
British American Tobacco PLC - London-based cigarette and nicotine product maker - Hires UBS AG London Branch, part of UBS Group AG, to run the first tranche of the GBP1.3 billion extension to its share buyback programme that BAT had announced on Tuesday. The tranche will start on January 2 and be completed by February 11. BAT will release its 2025 results the next day, on February 12. BAT currently is in the process of completing a GBP1.60 billion share buyback launched back in 2024. The buybacks are partly to return the proceeds of BAT's sale of part of its stake in India's ITC Hotels Ltd. Read More
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of the US Federal Reserve interest rate decision. Read More
(Alliance News) - Volution Group PLC on Wednesday said it expects to deliver another year of good growth in revenue, operating profit and cash generation as it announced the acquisition of Australia's AC Industries. Read More
GSK PLC - London-based pharmaceutical maker - US regulator the Food & Drug Administration grants orphan drug designation to a GSK treatment for small-cell lung cancer. The designation is for drugs that address a rare disease or condition. It grants benefits including a period of market exclusivity. GSK'227, known as risvutatug rezetecan, already had orphan drug designation from the European Medicines Agency for the treatment of pulmonary neuroendocrine carcinoma, a category that includes small-cell lung cancer. SCLC constitutes about 13% of all lung cancers in the US. Risvutatug rezetecan is a B7-H3-targeted antibody-drug conjugate for which GSK acquired exclusive worldwide rights, excluding greater China, from Jiangsu Hansoh Pharmaceutical Group Co Ltd. Read More
(Alliance News) - FirstGroup PLC on Wednesday said it has been named the preferred operator of the London Overground suburban rail network by Transport for London. Read More
(Alliance News) - Stocks were called lower on Wednesday, as investors prepare for the US Federal Reserve's interest rate decision and subsequent press conference. Read More
(Alliance News) - Stocks in London are set to open lower on Wednesday, ahead of the US Federal Reserve's interest rate decision. Read More
(Alliance News) - Welcome to the Alliance News UK service (ISSN 2515-9453), consisting of the Alliance News UK Professional and its family of financial newswires serving investors and their professional advisers. Read More
(Alliance News) - Europe's leaders must rehash how a major human rights treaty is interpreted in law to tackle illegal migration and prevent voters from turning to "the forces that seek to divide us", Sir Keir Starmer has said. Read More
(Alliance News) - Britain on Tuesday sanctioned entities it accused of distorting information in favour of Russia as well as two Chinese companies for alleged cyber activities against the UK and its allies. Read More